Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02447861 · ClinicalTrials.gov registry record

The 3q29 Deletion and 3q29 Duplication: Architecture of Behavioral Phenotypes

A clinical trial of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
800
Enrollment target
1
Study location

NCT02447861 is a study of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 800 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02447861, a study of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
800 participants
Enrollment target
1
Study location

Study Summary

The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.

Study Locations (1)

New Jersey

  • Internet-Based - Piscataway

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2013-07
Est. Completion 2028-01

What the Registry Record Tells You About NCT02447861

The ClinicalTrials.gov registry entry for NCT02447861 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Microdeletion 3q29 Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT02447861 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02447861 about?

NCT02447861 is a clinical study titled "The 3q29 Deletion and 3q29 Duplication: Architecture of Behavioral Phenotypes". The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.

What is the current status of trial NCT02447861?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2013-07. Estimated completion is 2028-01.

What conditions does trial NCT02447861 study?

This clinical trial studies the following conditions: Microdeletion 3q29 Syndrome, Microduplication 3q29 Syndrome.

Who is sponsoring clinical trial NCT02447861?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02447861 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.